Characteristics | Group A: HCV/HIV co-infected patients, treated (n = 36) | Group B: HCV/HIV co-infected patients, untreated (n = 52) | p-values |
---|---|---|---|
Age, mean (min./max.) | 47 (26/64) | 45 (27/61) | 0.040 |
Sex, male/female (%) | 26/10 (72/28) | 40/12 (77/23) | 0.617 |
Genotype, n (%) | |||
1 | 15 (42) | 22 (42) | 0.952 |
2 | 2 (6) | 1 (2) | 0.356 |
3 | 14 (39) | 11 (21) | 0.070 |
4 | 1 (2) | 1 (2) | 0.791 |
Unknown | 4 (11) | 17 (33) | 0.020 |
Transmission of HCV, n (%) | |||
IVDU | 21 (58) | 37 (71) | 0.212 |
Transfusion | 4 (11) | 3 (6) | 0.363 |
Needlestick injury | 0 (0) | 0 (0) | n.a. |
Tatoo | 0 (0) | 0 (0) | n.a. |
Sex | 1 (3) | 3 (6) | 0.508 |
Unknown | 10 (28) | 9 (17) | 0.241 |
CDC Classification, n (%) | |||
A1 – A3 | 13 (36) | 10 (19) | 0.005 |
B1 – B3 | 9 (25) | 7 (13) | 0.168 |
C1 – C3 | 9 (25) | 22(42) | 0.059 |
Unknown | 5 (13) | 14 (26) | 0.144 |
Liver biopsy, n (%) | 7/36 (19) | 5/52 (9) | 0.186 |
Fibrosis F3 – F4, n (%) | 5/7 (71) | 1/5 (20) | 0.029 |
HCV RNA in IU/ml, mean (min./max.) | 4800 000 (800/9 × 107) | 4 713 000 (3/6 × 107) | 0.965 |
CD4 Count absolute, mean | 553,1 | 396,73 | 0.001 |
CD4 Count > 200/μl, n (%) | 25 (69) | 21 (40) | 0.007 |
CD4 Count < 200/μl, n | 2 (3,5) | 16 (30) | 0.004 |
CD4 Count unknown, n (%) | 7 (19) | 15 (28) | 0.317 |
CD4 Count relative, mean | 27,9 | 22,2 | 0.001 |
CD4 Nadir in cells/μl, mean | 208 | 194 | 0.689 |
CD4/CD8 Ratio, mean | 0,67 | 0,49 | 0.001 |
HIV RNA in copy/ml, mean (minimum/maximum) | 9 850 (3/16 × 104) | 71 180 (3/12 × 105) | 0.015 |
HIV Treatment, n (%) | 29 (36) | 0 (0) | n.a. |
NRTI, n (%) | 20/29 (68) | n.a. | n.a. |
NNRTI, n (%) | 18/29 (62) | n.a. | n.a. |
PI, n (%) | 12/29 (41) | n.a. | n.a. |
Intregrase Inh., n (%) | 2/29 (6) | n.a. | n.a. |
Entry Inh., n (%) | 0 (0) | n.a. | n.a. |